Expert Interview
Looking at Vera Therapeutics 96-week eGFR Stabilization data in the ORIGIN Phase 2b Study of Atacicept in IgAN
Ticker(s): VERAInstitution: Baylor/Texas A&M
- Clinical Assistant Professor of Medicine at Texas A&M University, Staff Physician at the Baylor Regional Transplant Institute, and partner at Dallas Nephrology Associates
- Manages 75 patients a week with kidney disease with a focus on chronic kidney disease, end stage renal disease, transplantation, and dialysis.
- Active in clinical research and is published in international journals in both nephrology and transplantation.
Could you please explain the mechanism of action of atacicept and how it differentiates from other treatments available for IgAN, especially considering its dual inhibition of BAFF and APRIL?
Added By: ben_adminBased on the week 96 data from the Phase 2b ORIGIN study, how does atacicept's efficacy compare to other IgAN treatments?
Added By: ben_adminHow many patients with IgAN do you manage? Can you discuss the current standard of care?
Added By: ben_adminWhat makes Atacicept’s dual pathway targeting of BAFF and APRIL promising in treating IgAN, and how does it compare to current options in reducing proteinuria, microscopic hematuria, and eGFR decline?
Added By: catalin_adminCould Atacicept potentially become a first-line treatment for patients with higher proteinuria levels, and are there other patient profiles that might particularly benefit from this targeted approach?
Added By: catalin_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
